LQDA Liquidia Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1819576 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY2,233.6%
TTM net income YoY192.7%
TTM EPS YoY178.2%
Revenue 3-yr CAGR193.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin37.4%
Net margin30.7%
FCF margin33.4%
EBITDA margin37.7%
Returns
ROE131.8%
ROA35.6%
ROIC (approx.)—
Asset turnover1.16x
Leverage & solvency
Liabilities / assets62.6%
Debt / equity0.00x
Current ratio2.31x
Interest coverage6.33x
Cash quality & payout
Operating cash flow / net income1.21x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $225.30M | $171.68M | $132.87M | $92.02M | $54.34M | $8.84M | $3.12M | $2.92M |
| Cost of revenue | — | — | — | — | — | — | $1.52M | $1.35M |
| Gross profit | — | — | — | — | — | — | $1.60M | $1.56M |
| R&D expense | $25.27M | $17.18M | $12.57M | $16.94M | $9.35M | $6.02M | $6.97M | $16.48M |
| SG&A expense | $59.02M | $57.43M | $46.94M | $48.24M | $40.06M | $38.82M | $30.06M | $21.20M |
| Operating income | -$263.52M | $85.52M | $61.50M | $19.79M | $1.77M | -$37.51M | -$35.42M | -$36.11M |
| Interest expense | — | $6.30M | $6.49M | $6.90M | $6.95M | $5.66M | $4.67M | $4.51M |
| Pretax income | -$266.40M | $81.70M | $56.78M | — | -$3.53M | -$41.58M | -$38.37M | — |
| Income tax | -$30.07M | $6.97M | $3.92M | $0 | $0 | $0 | $0 | — |
| Net income | -$236.33M | $74.72M | $52.86M | $14.55M | -$3.53M | -$41.58M | -$38.37M | -$38.51M |
| EBITDA | -$263.32M | $85.82M | $62.00M | $20.11M | $2.07M | -$37.30M | -$34.97M | -$35.59M |
| EPS (basic) | -2.64 | 0.84 | 0.60 | — | -0.04 | -0.49 | -0.45 | — |
| EPS (diluted) | -2.64 | 0.74 | 0.52 | — | -0.04 | -0.49 | -0.45 | — |
| Weighted avg. shares (diluted) | 89.52M | 101.40M | 101.11M | — | 86.33M | 85.59M | 85.17M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $396.09M | $284.18M | $222.79M | $190.68M | $157.50M | $173.42M | $169.76M | $176.48M |
| Receivables | $106.75M | $108.58M | $74.16M | $54.09M | $35.96M | $9.97M | $1.25M | $2.72M |
| Inventory | $36.17M | $36.18M | $28.51M | $23.80M | $24.53M | $6.44M | $1.35M | $241,000 |
| Current assets | $596.72M | $437.71M | $333.06M | $273.40M | $226.72M | $195.58M | $177.21M | $185.10M |
| PP&E, net | $44.51M | $34.55M | $20.84M | $11.84M | $10.70M | $9.54M | $8.48M | $8.30M |
| Goodwill | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M |
| Intangibles | — | $2.85M | $2.89M | $2.95M | $2.99M | $3.05M | $3.11M | $3.16M |
| Total assets | $682.94M | $521.92M | $401.53M | $327.93M | $275.98M | $257.41M | $227.43M | $230.31M |
| Current liabilities | $585.40M | $189.30M | $149.74M | $135.77M | $102.94M | $78.41M | $60.52M | $41.78M |
| Total liabilities | $708.38M | $326.80M | $292.95M | $283.19M | $253.93M | $242.22M | $177.72M | $150.94M |
| Shareholders' equity | -$25.43M | $195.11M | $108.58M | $44.75M | $22.05M | $15.19M | $49.71M | $79.38M |
| Shares outstanding | 89.73M | 89.10M | 88.31M | 87.20M | 86.82M | 85.86M | 85.30M | 84.68M |
| Cash flow statement | ||||||||
| Operating cash flow | $146.68M | $80.24M | $52.99M | $44.24M | -$9.77M | -$39.48M | -$30.68M | -$20.81M |
| Capital expenditure | $16.90M | $11.23M | $2.83M | $2.04M | $911,000 | $1.06M | $330,000 | $1.29M |
| Free cash flow | $129.78M | $69.01M | $50.16M | $42.21M | -$10.68M | -$40.54M | -$31.01M | -$22.10M |
| Investing cash flow | -$16.90M | -$12.23M | -$2.83M | -$4.04M | -$911,000 | -$1.06M | -$330,000 | -$4.78M |
| Financing cash flow | -$17.87M | -$6.61M | -$18.05M | -$7.02M | -$5.25M | $47.71M | $24.29M | -$2.30M |
| Depreciation & amortization | $200,000 | $300,000 | $497,000 | $320,000 | $300,000 | $200,000 | $451,000 | $518,000 |
| Stock-based compensation | $13.68M | $10.37M | $9.22M | $7.21M | $7.90M | $6.93M | $7.44M | $5.03M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.